Eli Lilly (NYSE: LLY) has been one of the best-performing healthcare giants over the past decade. It now stands as the ...

These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.

Please provide your email address to receive an email when new articles are posted on . HF with preserved ejection fraction is common among people with obesity and type 2 diabetes. New real-world data ...

Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...

Tirzepatide demonstrated superior cost-effectiveness compared to semaglutide for knee OA and obesity, with a $57,400 per QALY threshold. The Osteoarthritis Policy Model assessed cost-effectiveness, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Youths receiving tirzepatide had a 2.28 percentage point ...

New research shows that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes ...